You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)就漢達遠®(阿達木單抗注射液)與GETZ PHARMA訂立許可協議
格隆匯 02-23 18:12

格隆匯2月23日丨復宏漢霖(02696.HK)發佈公吿,公司及其附屬公司上海復宏漢霖生物製藥有限公司已於2022年2月23日與Getz Pharma (Private) Limited及其聯屬公司Getz Pharma International FZ-LLC(統稱為“Getz Pharma”)訂立許可及供應協議,據此,公司同意向Getz Pharma授出許可,供其於巴基斯坦伊斯蘭共和國,菲律賓,越南,緬甸,柬埔寨,尼日利亞,肯尼亞,斯里蘭卡,烏克蘭,哈薩克斯坦,烏茲別克斯坦以及互相商定的任何其他地區商業化阿達木單抗注射液(中國境內商品名:漢達®)。

根據披露,漢達遠® (阿達木單抗注射液)是該公司自主研發的阿達木單抗生物類似藥,於2020年12月獲國家藥品監督管理局(NMPA)批准於中國境內上市。截至該公吿日,漢達遠®於中國境內獲批的適應症為(1)類風濕關節炎;(2)強直性脊柱炎;(3)銀屑病;及(4)葡萄膜炎。根據該公司與上海復星醫藥(集團)股份有限公司附屬公司江蘇萬邦生化醫藥集團有限責任公司於2017 年9月簽訂的合作協定,漢達遠®上市後的中國境內商業化銷售將由江蘇萬邦負責。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account